Bankruptcy Was Good for 23andMe

Anne Wojcicki, founder and controlling shareholder of 23andMe Holding Co. with approximately 49% of voting power, proposed taking the struggling genetic testing company private to address its issues away from public market pressures. However, the board of directors deemed Wojcicki's offer insufficient, as they are obligated to find a proposal that best serves the interests of non-affiliated shareholders.

Analysis

23andMe Holding Co., a genetic testing company once valued at approximately $6 billion, is currently navigating significant financial distress, prompting its founder and controlling shareholder, Anne Wojcicki, who holds about 49% of the voting power, to propose taking the company private. Wojcicki's rationale is to address the company's challenges away from the "short term pressures of the public markets." However, this privatization bid has encountered a roadblock, as the company's board of directors has rejected the offer, deeming it insufficient and not in the best interests of non-affiliated shareholders. This situation underscores a common governance conflict where a controlling shareholder's desire to acquire the company at a potentially low price clashes with the board's fiduciary duty to maximize value for all shareholders. The rejection introduces uncertainty regarding the company's strategic direction and the resolution of its ongoing operational and financial difficulties, reflecting a moderately negative outlook for its immediate future.

Key Decisions for Investors

• Investors should recognize the current impasse between 23andMe's controlling shareholder and its board regarding the privatization offer, which creates significant uncertainty for the stock's valuation and future prospects.
• Monitor closely for any revised offers from Anne Wojcicki or alternative strategic plans announced by the board, as these developments will be critical in assessing the potential outcomes for non-affiliated shareholders.
• Given the company's acknowledged "hard times" and the prevailing pessimistic sentiment surrounding the rejected bid, shareholders should evaluate their exposure and consider the heightened risk profile until a clear path forward is established.